Abstract
Polyglutamine (polyQ) diseases are inherited neurodegenerative disorders caused by proteins with expanded polyQ regions. Although the pathological mechanisms of these diseases have not yet been elucidated, the processes of protein misfolding and aggregation seem to be a direct cause of neurodegeneration. Detailed structural information on polyQ proteins is therefore essential in order to understand the mechanisms underlying pathogenesis and to design therapeutic strategies. In the past decade, several studies have investigated the structural properties of polyQ proteins and the molecular basis of aggregation and fibre formation. The results obtained in these studies are reviewed here.
Keywords: polyglutamine, aggregation, neurodegenerative diseases, structure, triplet expansion
Protein & Peptide Letters
Title: Polyglutamine and Neurodegeneration: Structural Aspects
Volume: 11 Issue: 3
Author(s): Laura Masino
Affiliation:
Keywords: polyglutamine, aggregation, neurodegenerative diseases, structure, triplet expansion
Abstract: Polyglutamine (polyQ) diseases are inherited neurodegenerative disorders caused by proteins with expanded polyQ regions. Although the pathological mechanisms of these diseases have not yet been elucidated, the processes of protein misfolding and aggregation seem to be a direct cause of neurodegeneration. Detailed structural information on polyQ proteins is therefore essential in order to understand the mechanisms underlying pathogenesis and to design therapeutic strategies. In the past decade, several studies have investigated the structural properties of polyQ proteins and the molecular basis of aggregation and fibre formation. The results obtained in these studies are reviewed here.
Export Options
About this article
Cite this article as:
Masino Laura, Polyglutamine and Neurodegeneration: Structural Aspects, Protein & Peptide Letters 2004; 11 (3) . https://dx.doi.org/10.2174/0929866043407147
DOI https://dx.doi.org/10.2174/0929866043407147 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Glial Reaction in Parkinsons Diseases: Inflammatory Activation Signaling of Glia as a Potential Therapeutic Target
Current Signal Transduction Therapy The Path from Anti Parkinson Drug Selegiline and Rasagiline to Multifunctional Neuroprotective Anti Alzheimer Drugs Ladostigil and M30
Current Alzheimer Research Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Resveratrol as a Potential Therapeutic Candidate for the Treatment and Management of Alzheimer's Disease
Current Topics in Medicinal Chemistry RNA Therapeutics Directed to the Non Coding Regions of APP mRNA, In Vivo Anti-Amyloid Efficacy of Paroxetine, Erythromycin, and N-acetyl cysteine
Current Alzheimer Research Nerve Growth Factor and Brain-Derived Neurotrophic Factor in Schizophrenia and Depression: Findings in Humans, and Animal Models
Current Neuropharmacology Pathophysiology of Neurodegeneration in Familial Amyotrophic Lateral Sclerosis
Current Molecular Medicine Thienyl Pyrimidine Derivatives with PrPSc Oligomer-Inducing Activity are a Promising Tool to Study Prions
Current Topics in Medicinal Chemistry Melatonin Receptor Agonists: SAR and Applications to the Treatment of Sleep-Wake Disorders
Current Topics in Medicinal Chemistry Nitric Oxide and Schizophrenia: Present Knowledge and Emerging Concepts of Therapy
CNS & Neurological Disorders - Drug Targets Structure-Activity Relationships of Glutamate Carboxypeptidase II (GCPII) Inhibitors
Current Medicinal Chemistry Gene Expression Studies in Multiple Sclerosis
Current Genomics A Synopsis on the Role of Tyrosine Hydroxylase in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Nanomedicine
Current Nanoscience Interplay between the APOE Genotype and Possible Plasma Biomarkers in Alzheimer’s Disease
Current Alzheimer Research Are we Genomic Mosaics? Variations of the Genome of Somatic Cells can Contribute to Diversify our Phenotypes
Current Genomics Current Developments of Coumarin Compounds in Medicinal Chemistry
Current Pharmaceutical Design Intracellular and Extracellular Zinc Detection by Organic Fluorescent Receptor
Current Organic Chemistry The Endocannabinoid System in Parkinsons Disease
Current Pharmaceutical Design Withdrawal Notice: Neuroprotective Effect of Lithospermum officinale callus Extract on Inflamed Primary Microglial Cells
Current Pharmaceutical Biotechnology